Metastatic Cutaneous Apocrine Adenocarcinoma Successfully Treated with Systemic Anti-androgen Therapy-A Case Report

Overview

Journal Clin Case Rep

Date 2020 Dec 28

PMID 33363954

Citations 3

Authors

Fanny Collette

Marc Hamoir

Pascal Van Eeckhout

Philippe dAbadie

Thierry Duprez

Sandra Schmitz

Jean-Pascal Machiels

Affiliations

Soon will be listed here.

Abstract

Primary cutaneous apocrine adenocarcinoma (PCAC) is an extremely rare neoplasm involving the sweat glands. Due to a lack of cases, there is no consensus for the systemic treatment of locally advanced or metastatic PCAC. Anti-androgen therapy may have activity in inoperable or metastatic PCAC with high androgen receptor (AR) expression.

Citing Articles

Apocrine adenocarcinoma of the head and neck district: Our experience with two cases.

Ferragina F, Barca I, Sorrentino A, Sottile A, Cristofaro M Int J Surg Case Rep. 2023; 112:109017.

PMID: 37931505 PMC: 10667934. DOI: 10.1016/j.ijscr.2023.109017.

Retroperitoneal Metastatic Apocrine Gland Ductal Adenocarcinoma in a Beagle Dog.

Moon C, Min H, Lee H, Jeong S, Kim D Vet Sci. 2022; 9(5).

PMID: 35622762 PMC: 9143555. DOI: 10.3390/vetsci9050234.

Metastatic cutaneous apocrine adenocarcinoma successfully treated with systemic anti-androgen therapy-A case report.

Collette F, Hamoir M, Van Eeckhout P, dAbadie P, Duprez T, Schmitz S Clin Case Rep. 2020; 8(12):3472-3478.

PMID: 33363954 PMC: 7752452. DOI: 10.1002/ccr3.3434.

References

Fujisawa Y, Fujimoto M . Metastatic cutaneous apocrine carcinoma of the axilla successfully treated using systemic chemotherapy with i.v. epirubicin and cyclophosphamide followed by oral fluorinated pyrimidine. J Dermatol. 2014; 41(3):280-2. DOI: 10.1111/1346-8138.12414. View

Collette F, Hamoir M, Van Eeckhout P, dAbadie P, Duprez T, Schmitz S . Metastatic cutaneous apocrine adenocarcinoma successfully treated with systemic anti-androgen therapy-A case report. Clin Case Rep. 2020; 8(12):3472-3478. PMC: 7752452. DOI: 10.1002/ccr3.3434. View

Otsuka M, Yamasaki O, Kaji T, Shien T, Iwatsuki K . Metastatic Cutaneous Apocrine Adenocarcinoma Treated With a Combination of Pertuzumab-Based Targeted Therapy and Taxane Chemotherapy: A Case Report. JAMA Dermatol. 2015; 152(1):111-3. DOI: 10.1001/jamadermatol.2015.2507. View

Ogata D, Kiyohara Y, Yoshikawa S, Kasami M . Treatment strategy for cutaneous apocrine carcinoma. Int J Clin Oncol. 2013; 19(4):712-5. DOI: 10.1007/s10147-013-0594-x. View

Choi I, Yun S . Large cutaneous apocrine carcinoma occurring on right thigh aggravated after moxa treatment. Ann Surg Treat Res. 2015; 88(5):294-7. PMC: 4422884. DOI: 10.4174/astr.2015.88.5.294. View

Bonnefoi H, Grellety T, Tredan O, Saghatchian M, Dalenc F, Mailliez A . A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1). Ann Oncol. 2016; 27(5):812-8. DOI: 10.1093/annonc/mdw067. View

Aldrees S, Zoroquiain P, Alghamdi S, Logan P, Kavalec C, Burnier M . Apocrine adenocarcinoma of the eyelid. Int J Ophthalmol. 2016; 9(7):1086-8. PMC: 4951669. DOI: 10.18240/ijo.2016.07.26. View

Armstrong A, Szmulewitz R, Petrylak D, Holzbeierlein J, Villers A, Azad A . ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol. 2019; 37(32):2974-2986. PMC: 6839905. DOI: 10.1200/JCO.19.00799. View

Pagano Boza C, Vigo R, Premoli J, Croxatto J, Gonzalez Barlatay J . A case report of a primary apocrine adenocarcinoma of the eyelid with literature review. Orbit. 2018; 37(5):389-392. DOI: 10.1080/01676830.2017.1423353. View

10.

Miller D, Peterson J, Buskirk S, Vallow L, Ta R, Joseph R . Management of Metastatic Apocrine Hidradenocarcinoma with Chemotherapy and Radiation. Rare Tumors. 2015; 7(3):6082. PMC: 4600998. DOI: 10.4081/rt.2015.6082. View

11.

Hibler B, Barker C, Hollmann T, Rossi A . Metastatic cutaneous apocrine carcinoma: Multidisciplinary approach achieving complete response with adjuvant chemoradiation. JAAD Case Rep. 2017; 3(3):259-262. PMC: 5447563. DOI: 10.1016/j.jdcr.2017.03.006. View

12.

Rogatsch M, Schmid J, Lax S, Uranitsch M, Schmid-Zalaudek K, Giuffrida R . Metastatic cutaneous apocrine adenocarcinoma responsive to the programmed cell death protein 1 inhibitor pembrolizumab. Eur J Cancer. 2017; 90:146-148. DOI: 10.1016/j.ejca.2017.11.008. View

13.

Chamberlain R, Huber K, White J . Apocrine gland carcinoma of the axilla: review of the literature and recommendations for treatment. Am J Clin Oncol. 1999; 22(2):131-5. DOI: 10.1097/00000421-199904000-00005. View

14.

Traina T, Miller K, Yardley D, Eakle J, Schwartzberg L, OShaughnessy J . Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer. J Clin Oncol. 2018; 36(9):884-890. PMC: 5858523. DOI: 10.1200/JCO.2016.71.3495. View

15.

Cardoso J, Calonje E . Malignant sweat gland tumours: an update. Histopathology. 2015; 67(5):589-606. DOI: 10.1111/his.12767. View

16.

Tolkachjov S, Brewer J, Bridges A . Apocrine Axillary Adenocarcinoma: An Aggressive Adnexal Tumor in Middle-Age Individuals. Dermatol Surg. 2018; 44(6):876-878. DOI: 10.1097/DSS.0000000000001430. View

17.

Misago N, Shinoda Y, Okawa T, Aoki S, Toda S, Koike K . Histiocytoid and signet-ring cell carcinoma of the axilla: a type of cutaneous apocrine carcinoma equivalent to histiocytoid lobular carcinoma of the breast?. Clin Exp Dermatol. 2011; 36(8):874-7. DOI: 10.1111/j.1365-2230.2011.04106.x. View

18.

Furudate S, Fujimura T, Tsukada A, Sato Y, Hidaka T, Tanita K . Successful Treatment of Advanced Primary Cutaneous Apocrine Carcinoma on the Scrotum with Systemic Chemotherapy and Radiotherapy Followed by Denosumab. Case Rep Oncol. 2017; 10(1):52-56. PMC: 5301092. DOI: 10.1159/000455091. View

19.

Fernandez-Flores A . Primary cutaneous apocrine carcinoma versus metastasis, a plea to the dermatopathology community. Am J Dermatopathol. 2010; 32(8):853-4. DOI: 10.1097/DAD.0b013e3181bbc473. View

20.

Loh S, Oh Y, Lew B, Sim W . Primary Cutaneous Apocrine Carcinoma. Ann Dermatol. 2016; 28(5):669-670. PMC: 5064209. DOI: 10.5021/ad.2016.28.5.669. View